Serum Amyloid A in lung transplantation

Sarcoidosis Vasc Diffuse Lung Dis. 2020;37(1):2-7. doi: 10.36141/svdld.v37i1.8775. Epub 2020 Mar 15.

Abstract

Background: Serum Amyloid A (SAA) is an acute phase protein and we analyzed its concentrations in lung transplantated patients (LTX).

Methods: 26 LTX patients (58.6 ± 11 years) and 11 healthy controls (55 ± 11.3 years). Three groups of LTX patients: acute rejection (AR, 7) bronchiolitis obliterans syndrome (BOS, 3), acute infection (INF, 9) and stable patients (NEG, 7).

Results: In LTX patients SAA concentrations were significantly increased, particularly in AR and INF. In LTX-AR patients were observed a correlation between SAA levels and peripheral CD4+ lymphocyte percentage (r=0.9, p<0.01) and a reverse correlation with FVC percentages (r -0.94, p=0.01).

Conclusions: SAA may represent a potential biomarker of LTX acute complications, with a prognostic value in AR. (Sarcoidosis Vasc Diffuse Lung Dis 2020; 37 (1): 2-7).

Keywords: lung transplantation; serum amyloid A; serum biomarkers.

Publication types

  • Comparative Study

MeSH terms

  • Acute Disease
  • Adult
  • Aged
  • Biomarkers / blood
  • Bronchiolitis Obliterans / blood*
  • Bronchiolitis Obliterans / diagnosis
  • Bronchiolitis Obliterans / immunology
  • Case-Control Studies
  • Female
  • Graft Rejection / blood*
  • Graft Rejection / diagnosis
  • Graft Rejection / immunology
  • Humans
  • Immunocompromised Host
  • Lung Transplantation / adverse effects*
  • Male
  • Middle Aged
  • Opportunistic Infections / blood*
  • Opportunistic Infections / diagnosis
  • Opportunistic Infections / immunology
  • Serum Amyloid A Protein / metabolism*
  • Treatment Outcome

Substances

  • Biomarkers
  • Serum Amyloid A Protein